Benefitting from Biosimilars — From Theory to Practice -

Benefitting from Biosimilars From Theory to Practice

Media formats available:

Details

Presenters

Overview
This 90-minute virtual activity will focus on understanding the best practices for using biosimilars when managing inflammatory conditions. Topics of discussion will be an overview of biologics and biosimilars, the biosimilar pathway, and strategies for integrating biosimilars into patient care.
This certified CE/CME activity is designed for gastroenterologists, nurses, nurse practitioners, pharmacists, physician assistants, primary care physicians, and rheumatologists involved in the care of patients with inflammatory conditions that can be treated with biosimilars.

This activity is supported by an independent medical education grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Define key elements of biosimilarity, including the distinction between biosimilars and generic drugs
- Describe the clinical development process and approval pathway for biosimilars
- Evaluate the benefits as well as the risks/drawbacks of integrating biosimilars into evidence-based patient treatment plans
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Faculty and Disclosures
Shubha Bhat, PharmD, MS, FCCP, BCACP
Clinical Pharmacy Specialist - Gastroenterology
Digestive Disease & Surgery Institute
Cleveland Clinic
Cleveland, OH

Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Professor of Medicine,
Healthcare Policy and Research
Weill Medical College of Cornell University
Attending Rheumatologist
Hospital for Special Surgery
New York, NY

Jonathan Kay, MD
Professor
Timothy S. and Elaine L. Peterson
Chair in Rheumatology
Professor of Medicine and Population and Quantitative Health Sciences
UMass Chan Medical School
UMass Memorial Medical Center
Worcester, MA

Edward V. Loftus Jr., MD
Professor of Medicine
Mayo Clinic College of Medicine
Co-Director, Advanced IBD Fellowship
Mayo Graduate School of Medicine
Consultant, Division of Gastroenterology
and Hepatology
Mayo Clinic
Rochester, MN

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Shubha Bhat, PharmD, MS, FCCP, BCACP, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, Pharmacosmos, and Prometheus Laboratories. Speaker's Bureau: Prometheus Laboratories.
Allan Gibofsky, MD, JD, MACR, FACP, FCLM, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Biosplice Therapeutics, BMS, Janssen, Novartis, and Pfizer. Speaker's Bureau: AbbVie, Amgen, and Pfizer. Stock/Shareholder: AbbVie, Janssen, Pfizer, and Regeneron Pharmaceuticals.
Jonathan Kay, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Alvotech Swiss AG, Boehringer Ingelheim GmbH, Bristol Myers Squibb, Fresenius Kabi, Novartis Pharmaceuticals, Organon, Samsung Bioepis, Sandoz, Scipher Medicine, and Teijin Pharma. Grant/Research Support: Aker BioMarine AS; Galapagos NV; and Novartis Pharmaceuticals. Royalties: Wolters Kluwer NV. Independent Data Monitoring Committee Member: Inmagene and Kolon TissueGene.
Edward V. Loftus Jr., MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Alvotech, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, CALIBR, Celgene, Celltrion Healthcare, Eli Lilly, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iterative Scopes, Janssen, Morphic, Ono Pharma, Pfizer, Protagonist, Scipher Medicine, Sun Pharmaceutical Industries, Surrozen, Takeda, and UCB. Grant/Research Support: AbbVie, Bristol-Myers Squibb, Celgene/Receptos, Genentech, Gilead, Gossamer Bio, Janssen, Pfizer, Takeda, Theravance, and UCB. Stock/Shareholder: Exact Sciences.
The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Boehringer Ingelheim Pharmaceuticals, Inc.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 03/03/2023

Shubha Bhat, PharmD, MS, FCCP, BCACP

Shubha Bhat, PharmD, MS, FCCP, BCACP

Allan Gibofsky, MD, JD, MACR, FACP, FCLM

Allan Gibofsky, MD, JD, MACR, FACP, FCLM

Jonathan Kay, MD

Jonathan Kay, MD

Edward V. Loftus Jr., MD

Edward V. Loftus Jr., MD

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

MinuteCE®
Signaling for Sustained Change: Spotlight on the Potential of TKIs to Deliver Durable Control of Exudative Retinal Disease
Katherine E. Talcott, MD; Christina Y. Weng, MD, MBA, FASRS
0.75 credits 5 episodes
- Katherine E. Talcott, MD
- Christina Y. Weng, MD, MBA, FASRS
- Roger A. Goldberg, MD, MBA
0.75 credits 5 episodes
Overcoming Cultural and Communication Disconnects, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Overcoming Cultural and Communication Disconnects, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
CME/CE
Overcoming Cultural and Communication Disconnects, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
David Chin Yee, MD, FASRS
0.25 credits
- David Chin Yee, MD, FASRS
0.25 credits
It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
CME/CE
It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
David Eichenbaum, MD
0.25 credits
- David Eichenbaum, MD
0.25 credits
A Case of Missed Diagnosis, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
A Case of Missed Diagnosis, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
CME/CE
A Case of Missed Diagnosis, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Esther Lee Kim, MD
0.25 credits
- Esther Lee Kim, MD
0.25 credits